It is well known that deficits in acetylcholine are intimately related to AD-associated cognitive decline, thus forming the basis of acetylcholinesterase (AChE)-based therapy in the disease (Bartus et al., 1982; Francis et al., 1999). Here, ACHE is linked to Alzheimer disease.